Abstract: The present invention provides a novel 11-step enantioselective approach to the natural product hyperforin, which enables access to a wide variety of hyperforin analogs. The present invention also provides pharmaceutical compositions comprising inventive hyperforin analogs. Hyperforin analogs synthesized using the present synthetic method are envisioned useful in the treatment of various conditions, including, but not limited to, depression and conditions characterized by depression, inflammatory skin conditions, diabetes, asthma, chronic obstructive pulmonary disease (COPD), kidney disorders, and ischemic brain damage.

Abstract: The invention describes methods and systems for making particular organic compounds from unsaturated fatty acids derived from biological materials. Particular embodiments describe synthesizing civetone and olefins from a mixture of palmitoleic and oleic unsaturated fatty acid esters. The inventive methods use reaction steps such as metathesis, cyclization, hydrolysis, and/or decarboxylation.

Abstract: Provided by the present invention is a method for efficient oxidation of alcohols by using, as a catalyst for dehydrogenation oxidation, a ruthenium complex which can be easily produced and easily handled and is obtainable at a relatively low cost. The invention relates to a method of producing a compound having a carbonyl group by dehydrogenation oxidation of alcohols by using as a catalyst the ruthenium carbonyl complex represented by the following general formula (1) RuXY(CO)(L) (1) (in the general formula (1), X and Y may be the same or different from each other and represent an anionic ligand, and L represents a tridentate aminodiphosphine ligand).

Abstract: The present invention relates to novel compounds and their use as fragrance materials.

Abstract: The present invention relates to a process for preparing cyclic compounds having at least eight carbon atoms and at least one keto group, to the cyclic compounds obtained by this process and to the use thereof, in particular as fragrance or for providing a fragrance.

Abstract: The present invention is directed to a novel fragrance compound, 3-methyl-cyclohexadec-6-enone.

Abstract: The present invention is directed to a novel fragrance compound, 3-methyl-cyclohexadec-6-enone.

Abstract: Provided by the present invention is a method for efficient oxidation of alcohols by using, as a catalyst for dehydrogenation oxidation, a ruthenium complex which can be easily produced and easily handled and is obtainable at a relatively low cost. The invention relates to a method of producing a compound having a carbonyl group by dehydrogenation oxidation of alcohols by using as a catalyst the ruthenium carbonyl complex represented by the following general formula (1) RuXY(CO)(L) (1) (in the general formula (1), X and Y may be the same or different from each other and represent an anionic ligand, and L represents a tridentate aminodiphosphine ligand).

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein.

Abstract: Novel compositions and methods for the treatment and prevention of malaria are disclosed herein.

Abstract: The present invention relates to compounds of Formula (I), wherein one R group is a hydrogen atom and the other is a hydrogen atom or a C1-3 alkyl group; and each carbon-carbon double bond of said compound, independently from each other, can be in a configuration Z or E or a mixture thereof; which are useful perfuming ingredients.

Abstract: The present invention relates to a process for preparing cyclic compounds having at least eight carbon atoms and at least one keto group, to the cyclic compounds obtained by this process and to the use thereof, in particular as fragrance or for providing a fragrance.

Abstract: The use of certain compounds for masking or decreasing the or one or a plurality of unpleasant olfactory impressions of one or a plurality of substances with an unpleasant odor and/or for enhancing the or one or a plurality of pleasant olfactory impressions of one or a plurality of substances with a pleasant odor and new fragrance mixtures and perfumed products containing such compounds.

Abstract: Ketones of the formula II where A is optionally alkyl-substituted C2-C12-alkanediyl, R1 and R2 are each, independently of one another, C1-C6-alkyl, or R1 and R2 together form optionally alkyl-substituted C3-C10-alkanediyl, and R3 is hydrogen or C1-C6-alkyl, are prepared by reacting a cyclic olefin of the formula I with dinitrogen monoxide to form the ketone of the formula II. The ketone of the formula II can be further hydrogenated to form the saturated ketone of the formula III. Macrocyclic ketones of the formula III, e.g. muscone, are sought after as fragrances.

Abstract: The present invention relates to a process for preparing at least one monocyclic ketone having from 4 to 20 carbon atoms by reacting a mixture G1 comprising at least one monocyclic olefin having from 4 to 20 carbon atoms with a mixture G2 comprising at least dinitrogen monoxide, wherein said reaction is performed adiabatically.

Abstract: The present invention is directed to a novel compound, 3-methyl-cyclohexadec-6-enone, and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of 3-methyl-cyclohexadec-6-enone.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein.

Abstract: A process and an apparatus for separating and recovering waste alkali from a cyclohexane oxidation solution are provided. A gradient combination of the gravity separation technique, the vortex separation technique and the coalescence separation technique is used to carry out fine separation of the waste alkali liquor from the cyclohexane oxidation solution. The purified cyclohexane oxidation solution is fed into a down-stream apparatus. Most of the waste alkali liquor thus separated is recycled, while the remaining is expelled. The expelled waste alkali liquor is incinerated in an incinerator, followed by recovering the molten species using a pneumatic pulverization process.

Abstract: In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight. In another aspect, the present invention provides a method for treating breast tumor metastasis in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the inventive composition described directly above and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract: The present invention provides compounds having formula (I): (I) wherein n, R1-R5, Ra-Rb, Q, Y1 and Y2 are as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis.

Abstract: (Problem) The object of the invention relates to a development of a new musk-feeling fragrance material which is a highly scenting musk-feeling fragrance, and is to provide a fragrance composition which, when added to fragrances or cosmetics, can improve the fixative property and express a high performance and excellent musky aromatic quality. (Means for resolution) A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 75:25 to 80:20 (weight ratio) in terms of weight ratio.

Abstract: The present invention relates to novel compounds and their use in fragrance compositions. Novel 3.2.1-bicyclo-octene and -octane compounds of the present invention are represented by formula: wherein R is selected from the group consisting of hydrogen, acetate, carbonate monomethyl ester, and allyloxy; and wherein the broken line represents a single or double bond.

Abstract: The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1—R6, Ra—Rc, Q, Y1, Y2 and n are as defined herein.

Abstract: A process for the oxidation of hydrocarbons comprises contacting the hydrocarbon with an oxygen-containing gas in the presence of a catalyst comprising a microporous solid support, preferably a zeolite, having from 8- to 12-ring open windows and comprising non-framework metal cations selected from manganese, iron, cobalt, vanadium, chromium, copper, nickel, and ruthenium, and mixtures thereof, providing that the oxygen-containing gas does not contain significant amounts of added hydrogen. The catalyst is novel and forms part of the invention. The process may be used for oxidation of alkanes, cycloalkanes, benzene and alkylbenzenes, and is suitable for use in regioselective terminal oxidation of straight chain alkanes and for selective oxidation/separation of p-dialkylbenzenes from an alkylbenzene mixture, for example, p-xylene from an isomeric mixture of xylenes.

Abstract: An electrode active material for a power storage device of the invention includes a ketone compound that includes a ring structure in a molecule, the ring structure being a five-membered or seven-membered ring composed of atoms at least three adjacent ones of which are each bonded to a ketone group. The electrode active material for a power storage device of the invention has a high weight-energy density and good reversibility of oxidation-reduction reaction. The use of the electrode active material for a power storage device of the invention can provide a power storage device having a high capacity, a high voltage, and good charge/discharge cycle characteristics.

Abstract: Disclosed are a catalyst including a hydrotalcite and, immobilized on a surface thereof, particles of at least one metal selected from the group consisting of Cu, Ag, and Au; a method for producing a carbonyl compound through dehydrogenation of an alcohol in the presence of the catalyst; and a method for producing a carbonyl compound through dehydrogenation of an alcohol in the presence of a catalyst including a hydrotalcite and, immobilized on a surface thereof, particles of a metal, in which dehydrogenation is performed in the absence of oxygen.

Abstract: The invention relates to a method for producing cyclohexadecanone by hydrogenating cyclohexadecenone, to mixtures of aromatic substances, and to products containing the inventive cyclohexadecanone.

Abstract: Described are spirocyclic ketols of formula (I) wherein n and A have the same meaning as given in the description. Also disclosed is a method for their production and flavour and fragrance compositions containing them.

Abstract: The present invention relates to a compound represented by the formula (I), method of preparation, pharmaceutical preparation containing said compound, and the use of said compound in the manufacture of a pharmaceutical preparation for the prevention and treatment of cancer by way of inhibiting the proliferation of carcinoma cells of the cervix and ovaries.

Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof for use as pharmaceutical compositions.

Abstract: Provided by the present invention are an adamantyl vinyl ether compound which is useful as a monomer for functional resins in the photolithography field or a raw material therefor and medical and agricultural intermediates and a production process for the same. The present invention relates to a production process for an adamantyl vinyl ether compound, characterized by subjecting an adamantyl vinyl ether compound having a specific structure and alcohol having an eliminating group in a ? position to chloroalkyl-etherification, then subjecting it to etherification to form an adamantyl group-containing ether and then subjecting it to vinyl-etherification.

Abstract: The present invention is directed to novel compounds of the structure and a method for enhancing a perfume composition by incorporating an olfactory acceptable amount of the compounds provided above.

Abstract: The invention relates to a compound of general formula (I) wherein: A) a) R4, R5, and R7 each represent a hydrogen atom and R3, R6 and R8 each represent a methyl radical, or b) R4, R6, and R7 each represent a hydrogen atom and R3, R5 and R8 each represent a methyl radical, or c) R3, R6 and R7 each represent a hydrogen atom and R4, R5 and R8 each represent a methyl radical, and the dotted lines are present and represent cis-double bonds or trans-double bonds, and R1 represents a hydrogen atom and R2 represents an OH, OCH3 or OC2H5 group, or the dotted lines are absent and R1 represents a hydrogen atom and R2 represents an OCH3 group or an OC2H5 group; or B) R1, R4, and R6 each represent a hydrogen atom and R2, R3 and R5 each represent a methyl radical, and the dotted lines are present and represent cis-double bonds or trans-double bonds, and R7 represents a hydrogen atom and R8 represents an OH, OCH3 or OC2H5 bond, or the dotted lines are absent and R7 represents a hydrogen atom and R8 represents an OCH3 group

Abstract: The invention relates to a method for producing monocyclic ketones C4-C5. The inventive method is based on the reaction of a liquid-phase oxidation of monocyclic alkenes C4-C5 into corresponding cyclic ketones by nitrogen oxide or the mixture thereof with an inert gas. The process is carried out at a temperature ranging from 20 to 300° C. and a pressure of nitrogen oxide ranging from 0,01 to 100 atm. The inventive process ensures the high selectivity with respect to target products, the explosion safety at work and is promising for industrial use.

Abstract: The invention relates to a method for producing macrocyclic ketones of general formula (I) by direct cyclisation of compounds of general formula (II) in the gas phase on a heterogeneous catalyst. In general formula (I), X represents a monounsaturated or polyunsaturated or saturated C10–C17 alkyl radical which can be optionally substituted by a C1–C6 alkyl radical, and in general formula (II), R1, R2 can respectively be the same or different and represent hydrogen or C1–C6 alkyl, and has the above-mentioned designation.

Abstract: The invention relates to the use of substituted bicyclo[3.3.1]nonan-2,4,9-triones, especially clusianon and clusianon derivatives, as pharmaceutical active ingredients or medicamentous active ingredients, especially for producing medicaments for the prophylactic and/or therapeutic (curative) treatment of tumour or cancer diseases, and of viral diseases. The above-mentioned compounds can be used in cytostatic agents and antiviral agents (virostatic agents). They are especially used as inhibitors of topoisomerases and telomerases and as regulators during the MAP kinase signal transduction and can thus intervene on a cellular scale in the mechanism for multiplication of tumour or cancer cells and viruses.

Abstract: The invention relates to a clusianon isomer and to the use thereof, in particular as a pharmaceutical or medical active ingredient, in particular for producing medicaments for the prophylactic and/or therapeutic (curative) treatment of tumor or cancer diseases as well as viral diseases. The aforementioned compound can be used in cytostatics and antiviral agents (virostatics). Said compound acts, in particular, as a topoisomerase and telomerase inhibitor and as a regulator in the MAP kinase signal transduction. Said compound can thus intervene at the cellular level in the proliferation mechanism of tumor or cancer cells and viruses.

Abstract: The compound (Z)-7-cyclohexadecen-1-one is described as a musk odorant. Also described are odorant or aroma mixtures comprising (Z)-7-cyclohexadecen-1-one and one or more other odorants or aromas.

Abstract: The invention relates to a method for producing monocyclic ketones C7–C20. The method of patent protection sought is based on the oxidation reaction of monocyclic alkenes C7–C20 into corresponding monocyclic ketones with nitrous oxide or a mixture thereof with inert gas. The process proceeds at a temperature ranging from 20 to 350° C. and a pressure of the nitrous oxide ranging from 0.01 to 100 atm. The process provides a high selectivity involving the target product, blast-resistant work operations and is promising for industrial use.

Abstract: The use of the reduction products of hyperforin and adhyperforin, pharmaceutically acceptable salts or esters thereof, in the pharmaceutical and/or nutritional field, in particular in the treatment of depression and Alzheimer's disease.

Abstract: The present invention provides a process for producing cycloalkanol and/or cycloalkanone by oxidizing cycloalkane with molecular oxygen in the presence of a heteropolyacid compound comprising a cobalt atom as a central element and a cobalt atom as a frame element.

Abstract: Hyperforin and adhyperforin halogenated derivatives of general formula (I) in which X, R and R1 have the meanings as defined in the disclosure, the process for the preparation thereof and the use thereof in the pharmaceutical and/or nutritional field, in particular in the treatment of depression, and Alzheimer's disease.

Abstract: A method for producing a ketone, particularly a macrocyclic ketone, from a 2-hydroxycycloalkanone having from 12 to 18 carbon atoms by efficiently dehydrating and reducing the acyloin in a single reaction vessel. A method for producing a ketone compound, which comprises dehydrating and reducing an acyloin in the coexistence of an acid catalyst and a reduction catalyst and in the presence of hydrogen, particularly using a 2-hydroxycycloalkanone having from 12 to 18 carbon atoms as the acyloin.

Abstract: The invention provides a process for the catalytic oxidation of an alkane, which comprises contacting the alkane with a source of oxygen in the presence of a catalyst comprising a compound of the formula (2) where R1 and R2 independently represent a hydrogen atom, a halogen atom, an alkyl group, an aryl group, a cycloalkyl group, a hydroxyl group, an alkoxy group, a carboxyl group, an alkoxycarbonyl group, or an acyl group, or R1 and R2 may together form a double bond or an aromatic or non-aromatic ring; Y represents an oxygen atom or a sulfur atom; X represents an oxygen atom or a hydroxyl group; m denotes an integer of 0 to 4; and n denotes an integer of 1 to 3. Compounds in accordance with formula (2) possess good catalytic properties, such that when they are employed in a process in accordance with the present invention, they are capable of activating a source of oxygen and promoting the oxidation of an alkane at mild reaction temperatures.

Abstract: The present invention relates to a novel thermo-isomerization method for rapidly and simply producing macrocyclic ketones of the formula Ia or Ib. The macrocyclic ketones are prepared in the gas phase at temperatures above 500° C. rapidly and in a simple manner from alcohols of the formula IIa and IIb directly with a high yield. In the formulae Ia, Ib, IIa and IIb, R1-R5, and n have the meanings given in the description.

Abstract: A method for liquid phase oxidation of a cycloalkane compound is provided by which the cycloalkane compound intended to be oxidized mixes with water to form an azeotropic mixture, and then an oxygen enriched gas is introduced to perform an oxidation reaction. This method is particularly suitable for liquid phase oxidation of cyclohexane by using an oxygen enriched gas or pure oxygen, which not only enhances conversion rate and selectivity of the cyclohexane oxidation process but also improves process safety in the use of an oxygen enriched gas or pure oxygen for cyclohexane oxidation.

Abstract: The present invention relates to novel tropolone compounds of the present invention and to oral care compositions suitable for preventing or treating diseases or conditions of the oral cavity in warm-blooded animals including humans, comprising an oral care effective amount of at least one novel tropolone compounds, and a pharmaceutically acceptable oral carrier. This invention further relates to a method for preventing or treating diseases or conditions of the oral cavity in warm-blooded animals including humans, by applying an oral care effective amount of the oral care composition to the oral cavity.

Abstract: In the process for producing a cyclododecanone by isomerizing an epoxycyclododecane-containing starting material in the presence of an isomerization reaction catalyst containing lithium bromide and/or lithium iodide, in order to perform the reaction with high efficiency (high reaction rate) and high selectivity and stably produce a high-purity cyclododecanone in industry while maintaining a high-level reaction rate, the epoxycyclododecane-containing starting material is produced by contacting an epoxycyclododecadiene with hydrogen in the presence of a hydrogen-reduction catalyst and has a content of the hydroxyl group-containing cyclododecane compounds contained in the epoxycyclododecane-containing starting material controlled to 5 mol % or less.

Abstract: The present invention relates to a process for the preparation of compounds of formula I: wherein the substituents are as defined in claim 1, by conversion of a compound of formula II: reaction of that compound with a compound of formula IV: X—C(O)—Q??(IV), wherein X is a leaving group, to form a compound of formula V: and treatment of that compound in the presence of a base with catalytic amounts of cyanide ions.

Abstract: The use of the reduction products of hyperforin and adhyperforin, pharmaceutically acceptable salts or esters thereof, in the pharmaceutical and/or nutritional field, in particular in the treatment of depression and Alzheimer's disease.